NanoSyrinx appoints Anthony Johnson as non-executive director

NanoSyrinx has announced the appointment of Anthony Johnson MD to its board as non-executive director.
This appointment marks part of the company’s plans to expand and strengthen its leadership team as it prepares for further stages of development.
Prior to this role, Anthony worked as chief executive officer at Goldfinch Bio and is chair of the Board of Directors at Outrun Therapeutics. He also has 20 years of experience in senior and executive positions for various early-stage biotech and pharma companies, including senior vice president of Early Clinical Development at AstraZeneca and similar roles at companies such as Bristol Myers Squibb and GSK. Anthony also has experience in biotech fundraising.
Commenting on his new appointment, Anthony Johnson added: “Building on over a decade of fundamental research, NanoSyrinx is creating a truly unique and exciting platform technolog y for the targeted intracellular delivery of biological molecules to address a wide range of unmet medical needs. Already, the Company has built an excellent team and I am looking forward to working with them, harnessing both my interest and expertise in this field, to advance the technolog y and help deliver safe and effective medicines for patients.”
Dr Joe Healey, chief executive officer of NanoSyrinx, stated: “Tony’s experience as an outcome-driven pharmaceutical executive with extensive industry involvement, including in biotech fundraising, will be invaluable as we build momentum for the next stage of the Company’s development. Alongside existing Board members, including Dr Steve Taylor and Dr Jane Dancer, our team is in a fantastic position to drive this growth forward.”